BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2020

May 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2020-05-13

Reporting Person: Stonehouse Jon P (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-13	Emp. Stock Option (Right to Buy)	$3.23	A	157250	Acquired	2029-12-17	Common Stock (157250)	Direct

Footnotes

F1: On May 13, 2020, the Board of Directors determined that the initial data from part 3 of the BCX9930 phase 1 clinical trial represented successful results from a proof of concept study of BCX9930 and, as a result, that one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020.